Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+0.17%+3.62%+70.94%+109.68% 73.25B
+1.05%+15.41%+50.75%+92.65% 61.95B
-0.69%-3.91%+0.09%+486.24% 28.02B
+5.24%+5.33%+57.01%+17.77% 24.15B
+0.30%-1.05%-18.41%-16.79% 23.01B
-0.71%+5.26%+241.94%+427.03% 18.35B
0.00%+5.57%+39.57%-14.30% 19.46B
+3.83%+2.65%+25.00%+592.85% 15.92B
+1.39%+3.33%+40.47%+151.37% 12.96B
Average +1.06%+1.24%+56.37%+205.17% 30.79B
Weighted average by Cap. +0.93%+3.43%+55.68%+167.46%
Logo Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc is a Canada-based biotechnology company. The Company develops pharmaceutical products in the areas of infectious disease and oncology. Thallion Pharmaceuticals Inc's lead clinical program, Shigamabs, is a dual antibody product for the treatment of Shiga toxin-producing E. coli bacterial infections and has completed a Phase II clinical trial. The Company is a subsidiary of BELLUS Health.
Employees
-